Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS)
CNY 53.74
(0.43%)
CNY 53.74
(0.43%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.28 Billion CNY | 115.46% |
| 2022 | 597.41 Million CNY | 87.78% |
| 2021 | 318.13 Million CNY | -25.94% |
| 2020 | 429.54 Million CNY | 5.92% |
| 2019 | 405.53 Million CNY | 52.76% |
| 2018 | 265.46 Million CNY | -8.55% |
| 2017 | 290.27 Million CNY | 131.92% |
| 2016 | 125.15 Million CNY | 1.46% |
| 2015 | 123.35 Million CNY | -28.72% |
| 2014 | 173.04 Million CNY | 6.09% |
| 2013 | 163.12 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.41 Billion CNY | 9.67% |
| 2024 Q3 | 1.8 Billion CNY | 18.05% |
| 2024 Q2 | 1.52 Billion CNY | 8.24% |
| 2023 FY | 1.28 Billion CNY | 115.46% |
| 2023 Q2 | 694.1 Million CNY | 7.0% |
| 2023 Q3 | 927.68 Million CNY | 33.65% |
| 2023 Q4 | 1.28 Billion CNY | 38.75% |
| 2023 Q1 | 648.69 Million CNY | 8.58% |
| 2022 Q3 | 526.12 Million CNY | 7.52% |
| 2022 Q2 | 489.31 Million CNY | 47.02% |
| 2022 Q1 | 332.81 Million CNY | 4.61% |
| 2022 FY | 597.41 Million CNY | 87.78% |
| 2022 Q4 | 597.41 Million CNY | 13.55% |
| 2021 Q4 | 318.13 Million CNY | 22.82% |
| 2021 Q1 | 383.89 Million CNY | -10.63% |
| 2021 FY | 318.13 Million CNY | -25.94% |
| 2021 Q3 | 259.01 Million CNY | 16.7% |
| 2021 Q2 | 221.96 Million CNY | -42.18% |
| 2020 FY | 429.54 Million CNY | 5.92% |
| 2020 Q4 | 429.54 Million CNY | 1.49% |
| 2020 Q3 | 423.25 Million CNY | -6.72% |
| 2020 Q2 | 453.73 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q3 | 331.3 Million CNY | 30.92% |
| 2019 Q2 | 253.06 Million CNY | 28.04% |
| 2019 Q4 | 405.53 Million CNY | 22.41% |
| 2019 FY | 405.53 Million CNY | 52.76% |
| 2019 Q1 | 197.64 Million CNY | -25.55% |
| 2018 Q2 | 239.12 Million CNY | -7.52% |
| 2018 Q1 | 258.57 Million CNY | -6.13% |
| 2018 FY | 265.46 Million CNY | -8.55% |
| 2018 Q4 | 265.46 Million CNY | 13.42% |
| 2018 Q3 | 234.05 Million CNY | -2.12% |
| 2017 FY | 290.27 Million CNY | 131.92% |
| 2017 Q4 | 275.46 Million CNY | 0.0% |
| 2017 Q1 | - CNY | -100.0% |
| 2016 Q4 | 120.4 Million CNY | 0.0% |
| 2016 Q2 | 103.45 Million CNY | 0.0% |
| 2016 Q3 | 120.4 Million CNY | 16.39% |
| 2016 FY | 125.15 Million CNY | 1.46% |
| 2016 Q1 | 103.45 Million CNY | -16.13% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 Q4 | 123.35 Million CNY | 0.0% |
| 2015 FY | 123.35 Million CNY | -28.72% |
| 2015 Q3 | 123.35 Million CNY | 0.0% |
| 2014 FY | 173.04 Million CNY | 6.09% |
| 2013 FY | 163.12 Million CNY | 0.0% |